Brofaromine Hydrochloride is a reversible inhibitor of monoamine oxidase A and acts on epinephrine , norepinephrine, serotonin, and dopamine. The compound was primarily researched in the treatment of depression and anxiety. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia. References: Urichuk LJ, Allison K, Holt A, Greenshaw AJ, Baker GB. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration. J Affect Disord. 2000 May;58(2):135-44. PubMed PMID: 10781703.

纯度：≥98%

CAS：63638-90-4